Last reviewed · How we verify

Anti-TNF

Abu Dhabi Stem Cells Center · FDA-approved active Small molecule Quality 5/100

Anti-TNF is a Small molecule drug developed by Abu Dhabi Stem Cells Center. It is currently FDA-approved. Also known as: Adalimumab, etanercept, certolizumab, or golimumab, Remicade, Humira, Cimzia.

At a glance

Generic nameAnti-TNF
Also known asAdalimumab, etanercept, certolizumab, or golimumab, Remicade, Humira, Cimzia
SponsorAbu Dhabi Stem Cells Center
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Anti-TNF

What is Anti-TNF?

Anti-TNF is a Small molecule drug developed by Abu Dhabi Stem Cells Center.

Who makes Anti-TNF?

Anti-TNF is developed and marketed by Abu Dhabi Stem Cells Center (see full Abu Dhabi Stem Cells Center pipeline at /company/abu-dhabi-stem-cells-center).

Is Anti-TNF also known as anything else?

Anti-TNF is also known as Adalimumab, etanercept, certolizumab, or golimumab, Remicade, Humira, Cimzia.

What development phase is Anti-TNF in?

Anti-TNF is FDA-approved (marketed).

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing